Azitra, Inc. (AZTR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing precision dermatology therapies using genetically engineered microbes. The company operates as a single segment and is currently in the pre-commercialization phase with no product revenue. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Total Revenue | $0 | $0 | - |
| Net Loss | $(2,888,993) | $(5,957,338) | - |
| Operating Expenses | $2,871,352 | $5,971,590 | - |
| Cash and Equivalents | - | - | $1,045,730 |
| Working Capital | - | - | $347,329 |
| Accumulated Deficit | - | - | $(63,523,164) |
| Long-Term Debt | - | - | $274,506 (Leases) |
Note: Working Capital calculated as Current Assets ($1,799,690) minus Current Liabilities ($1,452,361).
Material Changes vs. Prior Period
- Revenue: The company reported $0 revenue for the quarter and year-to-date, compared to $7,500 in related-party service revenue in the same periods of 2024. Management does not expect further service revenue.
- Operating Expenses: Total operating expenses increased by 8% ($203,572) in Q2 2025 compared to Q2 2024. Research and Development (R&D) expenses rose 25% to $1.4 million, driven by clinical trial progression for programs ATR-12 and ATR-04.
- Net Loss: Net loss increased by 10% to approximately $2.9 million for the quarter, primarily due to higher R&D costs and a decrease in other income (specifically a reduction in the gain from the change in fair value of warrants).
- Cash Position: Cash and cash equivalents decreased by approximately $3.5 million during the first six months of 2025, driven by a net cash burn of $5.9 million from operating activities, partially offset by $2.4 million in financing proceeds.
Outlook, Risks, and Management Commentary
- Going Concern: Management has identified substantial doubt about the company's ability to continue as a going concern for the next twelve months due to an accumulated deficit of $63.5 million, recurring losses, and a lack of commercial revenue. Additional financing is required to fund operations.
- Financing Activities: The company raised funds through follow-on public offerings in January and February 2025 and an Equity Line of Credit (ELOC) with Alumni Capital LP. As of August 11, 2025, $18.3 million remains available under the ELOC.
- Stock Split: Stockholders approved a potential further reverse stock split (ratio between 1:2 and 1:7) in February 2025 to maintain NYSE American compliance. The Board is currently evaluating the exact ratio.
- Clinical Progress:
- ATR-12: Phase 1b trial for Netherton syndrome; initial safety results reported in H1 2025.
- ATR-04: Phase 1/2 trial for EGFRi-associated rash; first patient expected to be dosed in Q3 2025.
- ATR-01: Lead optimization and IND-enabling studies planned for 2025.
- Internal Controls: Management identified a material weakness in disclosure controls and procedures related to a lack of adequate segregation of accounting functions.
- Risk Factors: Risks include the inability to secure additional funding, potential tariffs on imported goods/services, and the inherent risks of clinical development and regulatory approval.
Investor Verification Checklist
- Verify the sufficiency of the $1.0 million cash balance against the projected burn rate and the timeline for the next financing round.
- Confirm the status and terms of the Equity Line of Credit (ELOC) with Alumni Capital LP, including the 10% warrant issuance on future draws.
- Monitor the Board's decision on the reverse stock split ratio and its impact on share price and liquidity.
- Review the remediation plan for the material weakness in internal controls regarding segregation of duties.
- Track the clinical trial milestones for ATR-12 and ATR-04, as delays could significantly increase cash burn without revenue generation.